Also upcoming is a phase I/II study assessing an anti-T cell receptor β-chain constant domain 1 (TRBC1) CAR-T cell therapy in RR, TRBC1-expressing PTCL-NOS, AITL, and ALCL. This evidence concerns the gene TRBC1 and anaplastic large cell lymphoma.